Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company
20 juil. 2023 02h30 HE
|
Sosei Group Corporation
Transaction adds complementary late-stage clinical development capability with profitable and fast-growing commercial operations in JapanLean, go-to-market commercial model, well positioned to scale...
Sosei Heptares Webinar Presentation for Q2 FY2023 Financial Results
11 juil. 2023 03h00 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 11 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June...
Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia
02 juil. 2023 20h23 HE
|
Sosei Group Corporation
HTL’149 has been designed as a once-daily oral treatment to address positive and negative symptoms and cognitive impairment in schizophrenia patients without the adverse effects typically associated...
Sosei Heptares Provides Update on Lotiglipron Development
26 juin 2023 18h40 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 27 June 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) notes the decision by its partner Pfizer to prioritize the development of clinical-stage GLP-1...
Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2023
12 mai 2023 02h30 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 12 May 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter...
Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting
23 mars 2023 03h00 HE
|
Sosei Group Corporation
Eiko Tomita, Vice President, Global Regulatory Affairs at Bristol Myers Squibb, elected to the Company’s Board of DirectorsCandelle Chong promoted to Executive Vice President and Chief of Staff,...
Sosei Heptares Announces Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
14 mars 2023 20h05 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 15 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and...
Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
08 mars 2023 03h00 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 8 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and...
Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2022
14 févr. 2023 01h30 HE
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 14 February 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD)...
Sosei Heptares Webinar Presentation for FY2022 Financial Results
25 janv. 2023 01h30 HE
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused...